ADC

ClinicalJuly 28, 2026

Sonesitatug vedotin shows significant survival benefit in advanced gastric cancers

Sonesitatug vedotin demonstrated a statistically significant improvement in overall survival for patients with CLDN18.2-positive advanced gastric/GEJ cancers.

RegulatoryJuly 20, 2026

FDA Grants Priority Review for Datopotamab Deruxtecan Supplement

The FDA has granted priority review status for the supplemental application of Datopotamab Deruxtecan by Daiichi Sankyo.

RegulatoryJuly 17, 2026

FDA Grants Priority Review for ENHERTU Supplement Application

The FDA has granted priority review for the supplemental application of ENHERTU (fam-trastuzumab deruxtecan-nxki) submitted by Daiichi Sankyo.

RegulatoryJuly 15, 2026

FDA grants priority review for PADCEV supplemental application

The FDA has accepted a supplemental application for PADCEV (enfortumab vedotin-ejfv) from Astellas, granting it priority review status.

ClinicalJuly 11, 2026

Merck and Daiichi Sankyo Trial of Ifinatamab Deruxtecan in Advanced Esophageal Cancer

A clinical trial is underway to evaluate ifinatamab deruxtecan (I-DXd) for treating advanced esophageal squamous cell carcinoma.

ClinicalJuly 3, 2026

Bicycle Therapeutics Launches Continued Access Protocol for Investigational Products

Bicycle Therapeutics has initiated Continued Access Protocol (BiCAP) for patients benefiting from investigational treatments including zelenectide pevedotin, nuzefatide pevedotin, and BT7480.

RegulatoryJune 30, 2026

Enhertu Secures EU Approval as First Tumour Agnostic HER2 Therapy

Enhertu has been approved in the EU as the first tumour agnostic HER2-directed therapy for previously treated HER2-positive metastatic solid tumours.

RegulatoryJune 29, 2026

Datroway recommended for EU approval as 1st-line treatment for TNBC

Datroway has been recommended for approval in the EU as a 1st-line treatment for metastatic triple-negative breast cancer.

RegulatoryJune 25, 2026

FDA approves sacituzumab govitecan-hziy for first-line triple-negative breast cancer

The FDA has approved sacituzumab govitecan-hziy both as a monotherapy and in combination with pembrolizumab for the first-line treatment of triple-negative breast cancer.

CompetitiveJune 17, 2026

Overview of Antibody-Drug Conjugates in Cancer Therapy and Clinical Development

Antibody-drug conjugates (ADCs) have shown significant clinical benefits in advanced phase trials for various cancers, with over a dozen receiving FDA approval.

StrategyJune 16, 2026

Merck Acknowledges Daiichi Sankyo's ADC Manufacturing Update

Merck has acknowledged Daiichi Sankyo's update regarding its manufacturing and supply plan for ADC products.

RegulatoryJune 16, 2026

Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer

Datroway is approved in the US as the first TROP2-directed antibody drug conjugate for 1st-line treatment of metastatic triple-negative breast cancer.

ClinicalJune 16, 2026

Merck's Sacituzumab Tirumotecan Shows OS and PFS Improvement in Endometrial Cancer Phase 3 Trial

The TroFuse-005 trial demonstrated that sacituzumab tirumotecan significantly improved overall survival and progression-free survival compared to chemotherapy in patients with advanced or recurrent endometrial cancer.

CompetitiveJune 16, 2026

Pfizer and Innovent Collaborate on 12 Early-Stage Oncology Programs

Pfizer and Innovent Biologics have entered a strategic collaboration to co-develop 12 early-stage cancer medicines, including antibody-drug conjugates.

Companies

Assets

Recent signals(14)